ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 369

Association of Retroperitoneal Fibrosis with Malignancy and the Pathologic Features of Malignancy with Retroperitoneal Fibrosis

Sang Jin Lee1, Eon Jeong Nam2, Yeong Wook Song3 and Young Mo Kang4, 1Internal medicine, Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of (South), 2Internal Medicine, Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of (South), 3Dept of Internal Medicine, Seoul National Univ, Seoul, Korea, Republic of (South), 4Dept of Internal Medicine, Kyungpook National Univ Hosp, Daegu, Korea, Republic of (South)

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Pathophysiology, Retroperitoneal Fibrosing and cancer

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster I: Checkpoint Inhibitors, Retroperitoneal Fibrosis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Retroperitoneal fibrosis (RPF) is a periaortic sclerotic disease that encases adjacent structures, particularly the ureters. Because it is unclear whether RPF is associated with malignancy, we examined standardized incidence ratios (SIRs) of cancers in patients with RPF compared with age- and sex-matched general population. Subsequently, pathological differences between malignancy with RPF and malignancy without RPF were investigated.

Methods: Medical records of 111 patients diagnosed as having RPF by computed tomography, positron emission tomography (PET), and/or histological evaluation were reviewed. Forty one cases of cancers, which were confirmed by biopsies, were identified in 35 patients with RPF. Cancer incidence rates were calculated and compared with that observed in the Korean general population, computing the standardized incidence ratios (SIRs), which were then stratified according to RPF-cancer intervals. Cancer specimens with RPF (n=3) and cancer specimens without RPF (n=15), which were controls for age, sex, and cancer stage, were examined for the expression of interleukin (IL)-4, IL-10, PD-1, PD-L1, and IgG4/IgG by immunohistochemistry (IHC).

Results: The mean ± SD age at RPF diagnosis was 59.2 ± 15.0 years, and 69.4% of the patients were male. Ninety two cases (82.9%) showed peri-aortitis, and 65 cases (58.6%) presented with hydronephrosis. The cancer SIR (95% confidence intervals) in patients with RPF relative to age- and sex-matched individuals in the general population was 3.18 (2.23-4.41) [2.65 (1.70 – 3.94) in men; 5.34 (2.76 – 9.32) in women]. The most frequent cancer was unspecified urinary organ cancers with SIR of 733 (238 – 1711). SIRs of multiple myeloma [27.6 (3.34 – 99.6)], renal cell cancers [9.53, (1.15-34.4)] and adenocarcinoma of unknown primary cancers [16.9, (2.05 – 61.1)] were also significantly higher than in the general population. When stratified by RPF-cancer intervals, SIR was 10.4 (6.59 – 15.60) within 1 year of RPF diagnosis, while no significant increase in SIR was found out of 1 year around RPF. IHC analysis showed that the expressions of IL-4 and IL-10 in cancer tissues with RPF were higher than those in cancer tissues without RPF. However, there are no differences in the expression of PD-1, PD-L1 and IgG4/IgG between cancer tissues with RPF and those without RPF.

Conclusion: RPF was strongly associated with cancers within 1 year of RPF diagnosis. Immune environment of cancer tissues with RPF is different from that without RPF. That may contributed to the occurrence of RPF.


Disclosure: S. J. Lee, None; E. J. Nam, None; Y. W. Song, Astellas Pharma, Inc., 9; Y. M. Kang, None.

To cite this abstract in AMA style:

Lee SJ, Nam EJ, Song YW, Kang YM. Association of Retroperitoneal Fibrosis with Malignancy and the Pathologic Features of Malignancy with Retroperitoneal Fibrosis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/association-of-retroperitoneal-fibrosis-with-malignancy-and-the-pathologic-features-of-malignancy-with-retroperitoneal-fibrosis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-retroperitoneal-fibrosis-with-malignancy-and-the-pathologic-features-of-malignancy-with-retroperitoneal-fibrosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology